Sort
326,823 grants matching “clinical trial”
Improving the Clinical Effectiveness and Understanding of the Biophysical Basis
$2,343,081Thomas F Delaney · Massachusetts General Hospital · U19 · FY2014 · CA
Contemporary Treatment and Outcomes for Atrial Fibrillation in Clinical Practice
$2,342,937Alan S Go · Kaiser Foundation Research Institute · RC2 · FY2010 · HL
Rutgers-NYU Center for Asian Health Promotion and Equity
$2,342,923Soko Setoguchi-Iwata · Rutgers Biomedical And Health Sciences · P50 · FY2022 · MD
Cancer Center Support Grant
$2,342,788Richard A. Van Etten · University Of California-Irvine · P30 · FY2023 · CA
Cancer Center Support Grant
$2,342,475Robert Figlin · Beckman Research Institute/City Of Hope · P30 · FY2008 · CA
Cancer Center Support Grant
$2,342,475Robert Figlin · Beckman Research Institute/City Of Hope · P30 · FY2009 · CA
Spatiotemporal Tumor Analytics for Guiding Sequential Targeted-Inhibitor: Immunotherapy Combinations (ST-Analytics)
$2,342,452James R. Heath · Institute For Systems Biology · U54 · FY2024 · CA
Adverse Cerebrovascular Responses to Antibodies Targeting Beta-Amyloid
$2,342,415David Hastings Cribbs · University Of California-Irvine · RF1 · FY2024 · NS
BMT Clinical Research Network Data Coordinating Center
$2,342,210Medical College Of Wisconsin · U01 · FY2004 · HL
PLCO Trial Etiologic and Early Marker Study
$2,342,091Richard S Hayes · Division Of Cancer Epidemiology And Genetics · Z01 · FY2008 · CA
Collision of Alzheimers disease and COVID-19 pandemic in the United States: risks, outcomes, disparities and treatments
$2,342,002Rong Xu · Case Western Reserve University · RF1 · FY2022 · AG
Pharmacogenomics of Anti-platlet Intervention-2 (PAPI-2) Study
$2,341,982Alan R. Shuldiner · University Of Maryland Baltimore · U01 · FY2010 · HL
1/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis
$2,341,858Michael J Boeckh · Fred Hutchinson Cancer Research Center · UG3 · FY2020 · HL
CTSA INFRASTRUCTURE FOR CLINICAL TRIALS
$2,341,830Julianne L Imperato-McGinley · Weill Medical Coll Of Cornell Univ · UL1 · FY2010 · RR
A Randomized Controlled Trial of Electroconvulsive Therapy plus Usual Care versus Simulated-ECT plus Usual Care for the Acute Management of Severe Agitation in Alzheimer's Dementia (ECT-AD)
$2,341,700Brent Peter Forester · Mclean Hospital · R01 · FY2019 · AG
Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung Cancer
$2,341,652Roy S Herbst · Yale University · P50 · FY2025 · CA
UCSF PROSTATE CANCER SPORE
$2,341,539University Of California San Francisco · P50 · FY2000 · CA
Vaccine and Monoclonal Antibody Studies in HIV-infected Subjects
$2,341,505Julie E. Ledgerwood · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI
OPC SURVIVOR: Optimizing OroPharyngeal Cancer SURVIVORship
$2,341,478Katherine Arnold Hutcheson · University Of Tx Md Anderson Can Ctr · P01 · FY2025 · CA
Advancing Transplantation Outcomes in Children
$2,341,354David Michael Briscoe · Boston Children'S Hospital · U01 · FY2021 · AI
Cancer Research Consortium of West Michigan (CRCWM)
$2,341,117Kathleen J Yost · Corewell Health · UG1 · FY2017 · CA
Search for biomarkers to measure progression of diabetic nephropathy in Type 1 diabetes; application of proteomics technologies
$2,340,294Andrzej S Krolewski · Joslin Diabetes Center · DP3 · FY2016 · DK
Longitudinal Imaging Biomarkers of Prodromal DLB
$2,340,234Kejal Kantarci · Mayo Clinic Rochester · U01 · FY2025 · NS
Clinical Core
$2,340,055Joel Synes Perlmutter · University Of Pennsylvania · U19 · FY2024 · NS
NIDA DATA, STATISTICS, AND CLINICAL TRIAL SUPPORT CENTER MANAGEMENT AND SUPPORT. 09/05/2022 - 09/04/2023. N01DA-22-2253. TASK ORDER 75N95022F00001 (TO
$2,340,050Jennifer McCormack · The Emmes Company, Llc · N01 · FY2022 · DA